Nurses Revision

Hypothyroidism

Text size
On this page
Hypothyroidism is a clinical endocrine disorder resulting from insufficient production, secretion, or tissue action of thyroid hormones (triiodothyronine [T3] and thyroxine [T4]), leading to a generalized slowing of metabolic processes throughout the body.

Whereas thyrotoxicosis accelerates cellular metabolism and mimics excess adrenaline, hypothyroidism acts like a "slowing down" of every organ system. In adults, severe untreated hypothyroidism is termed myxedema, and its acute life-threatening decompensation is known as myxedema coma. In infants and children, severe untreated congenital or early-childhood hypothyroidism causes irreversible physical and neurological impairment historically termed cretinism.

Pathophysiology of Hypothyroidism

Normally, the hypothalamus releases Thyrotropin-Releasing Hormone (TRH), stimulating the anterior pituitary to secrete Thyroid-Stimulating Hormone (TSH), which drives the thyroid gland to synthesize T4 and T3 using dietary iodine. Peripheral tissues then deiodinate T4 into metabolically active T3.

  • Generalized Metabolic Slowing: Deficiency of T3 reduces nuclear gene transcription and Na+/K+-ATPase pump activity across cells, lowering oxygen consumption, heat generation (thermogenesis), and basal metabolic rate (BMR).
  • Reduced Sympathetic Responsiveness: Low thyroid hormone levels downregulate β-adrenergic receptors on the heart and blood vessels, causing bradycardia, decreased myocardial contractility, and reduced cardiac output.
  • Mucopolysaccharide Accumulation (Myxedema): Thyroid hormone deficiency impairs the breakdown of hydrophilic glycosaminoglycans (mucopolysaccharides, especially hyaluronic acid) in the dermis, subcutaneous tissues, tongue, vocal cords, and heart muscle. These complex sugars draw in water, producing characteristic firm, non-pitting tissue swelling known as myxedema.
  • Altered Lipid and Fluid Clearance: Decreased hepatic LDL-receptor expression slows cholesterol clearance (causing hyperlipidemia), while reduced renal free-water excretion and elevated antidiuretic hormone (ADH) predispose to hyponatremia.

Classification and Types of Hypothyroidism

Hypothyroidism is classified anatomically by the level of dysfunction along the hypothalamic–pituitary–thyroid (HPT) axis, as well as by age of onset, severity, and underlying cause.

1. Primary Hypothyroidism (> 95% of Cases)

Primary hypothyroidism originates from intrinsic failure or destruction of the thyroid gland itself. Because negative feedback to the pituitary is lost, serum TSH is elevated while Free T4 is low (in overt disease).

  • Overt Primary Hypothyroidism: Elevated serum TSH accompanied by low serum Free T4 and classic hypometabolic symptoms.
  • Subclinical (Mild) Primary Hypothyroidism: Elevated serum TSH alongside a normal serum Free T4. Patients are often asymptomatic or mildly fatigued; it may progress to overt hypothyroidism (especially if anti-TPO antibodies are positive or TSH > 10 mIU/L).
  • Hashimoto's Thyroiditis (Chronic Autoimmune Lymphocytic Thyroiditis): The leading cause of hypothyroidism in iodine-sufficient areas. The immune system produces autoantibodies (anti-thyroid peroxidase [anti-TPO] and anti-thyroglobulin) and cytotoxic T-cells that infiltrate and progressively destroy thyroid follicles. It may present with a firm, painless, rubbery goitre or an atrophic gland, and occasionally begins with a brief transient hyperthyroid phase ("Hashitoxicosis") before permanent hypothyroidism ensues.
  • Iodine-Deficiency Hypothyroidism: Severe dietary iodine shortage prevents synthesis of T3 and T4, triggering sustained TSH elevation and compensatory thyroid enlargement (endemic goitre).
  • Post-Ablative / Iatrogenic Hypothyroidism: Permanent thyroid failure following thyroidectomy (total or subtotal), radioactive iodine (131I) therapy for hyperthyroidism/thyroid cancer, or external beam radiation to the head and neck.
  • Drug-Induced Hypothyroidism: Caused by medications that block hormone synthesis or release—such as antithyroid drugs (carbimazole, methimazole, PTU), lithium, amiodarone (excess iodine Wolff–Chaikoff effect), interferon-α, and tyrosine kinase or immune checkpoint inhibitors.
  • Transient Hypothyroidism (Recovery Phase of Thyroiditis): Follows the initial destructive thyrotoxic phase of subacute (de Quervain's) thyroiditis or postpartum thyroiditis once stored hormone is depleted; thyroid function frequently recovers spontaneously over weeks to months, though some patients develop permanent hypothyroidism.

2. Secondary (Pituitary) and Tertiary (Hypothalamic) — Central Hypothyroidism

  • Secondary Hypothyroidism (Pituitary Failure): Caused by insufficient pituitary TSH secretion due to pituitary adenomas, pituitary surgery/radiotherapy, head trauma, infiltrative disease, or Sheehan's syndrome (postpartum pituitary necrosis following severe obstetric hemorrhage). Both Free T4 and TSH are low (or TSH is inappropriately normal despite low Free T4).
  • Tertiary Hypothyroidism (Hypothalamic Failure): Caused by hypothalamic tumours, irradiation, trauma, or granulomatous infiltration reducing TRH release, resulting in low TSH and low Free T4.

3. Congenital Hypothyroidism (Cretinism if Untreated)

Present at birth (occurring in roughly 1 in 2,000–4,000 newborns) due to thyroid dysgenesis (absent, hypoplastic, or ectopic gland), inherited enzymatic defects in hormone synthesis (dyshormonogenesis), severe maternal iodine deficiency during pregnancy, or transplacental passage of maternal antithyroid drugs or blocking antibodies. If not diagnosed and treated with levothyroxine in the first weeks of life, it results in permanent intellectual disability and stunted physical growth (cretinism).

4. Severe Decompensated Forms: Myxedema and Myxedema Coma

  • Myxedema: Severe, long-standing adult hypothyroidism marked by mucopolysaccharide infiltration of skin and viscera, coarse facial puffiness, non-pitting periorbital/pretibial edema, and pronounced psychomotor slowing.
  • Myxedema Coma: A rare, life-threatening medical emergency representing end-stage decompensation of severe hypothyroidism—presenting with hypothermia, bradycardia, hypotension, hypoventilation (hypercapnia), hyponatremia, hypoglycemia, and stupor or coma.

5. Peripheral (Consumptive or Receptor-Resistance) Hypothyroidism

Rare forms in which the thyroid gland produces hormone normally, but peripheral tissues fail to respond due to genetic mutations in thyroid hormone nuclear receptors (resistance to thyroid hormone) or rapid hormone inactivation by high-activity deiodinase enzymes (e.g., in large infantile hepatic hemangiomas).

Comparison: Primary vs. Subclinical vs. Secondary (Central) Hypothyroidism

FeatureOvert Primary HypothyroidismSubclinical Primary HypothyroidismSecondary / Tertiary (Central) Hypothyroidism
Site of LesionThyroid gland itself.Thyroid gland (early/mild impairment).Anterior pituitary (secondary) or hypothalamus (tertiary).
Serum TSHHigh (markedly elevated).Mildly High (above upper reference limit).Low or inappropriately normal.
Serum Free T4Low.Normal.Low.
Common CausesHashimoto's thyroiditis, iodine deficiency, post-thyroidectomy, post-RAI.Early Hashimoto's thyroiditis, recovery phase of thyroiditis, drugs.Pituitary adenoma/surgery, Sheehan's syndrome, cranial radiation.
Key Monitoring LabSerum TSH (target 0.5–4.5 mIU/L).Serial TSH & anti-TPO antibodies.Serum Free T4 (do not rely on TSH to adjust levothyroxine!).

Advertisements

Etiology and Risk Factors

Major Causes

  1. Autoimmune Destruction (Hashimoto's Thyroiditis): Most common cause in iodine-replete populations; strongly associated with female sex and middle age.
  2. Iodine Deficiency (and Dietary Goitrogens): Historically and globally a leading preventable cause of hypothyroidism, endemic goitre, and congenital cretinism in iodine-poor regions; exacerbated by diets heavy in poorly processed cassava or cruciferous goitrogens.
  3. Iatrogenic Ablation: Surgical removal of the thyroid gland, radioactive iodine (131I) treatment for Graves' disease or toxic goitre, and neck radiotherapy for lymphoma or head-and-neck cancers.
  4. Medications: Lithium (inhibits thyroid hormone release), amiodarone (excess iodine load), over-treatment with carbimazole/methimazole/PTU, and interferon/immunotherapy agents.
  5. Pituitary and Hypothalamic Disorders: Pituitary tumours, craniopharyngioma, neurosurgery, traumatic brain injury, and postpartum pituitary infarction (Sheehan's syndrome).
  6. Congenital Defects: Thyroid agenesis/ectopy or inherited defects in iodine trapping and organification.

Key Risk Factors

  • Demographics and Genetics: Female sex, age > 60 years, and family history of thyroid or autoimmune disorders.
  • Coexisting Autoimmune Conditions: Type 1 diabetes mellitus, pernicious anemia, Addison's disease (primary adrenal insufficiency), vitiligo, rheumatoid arthritis, and celiac disease.
  • Chromosomal and Obstetric Factors: Down syndrome, Turner syndrome, and the postpartum period (first 6–12 months after delivery).

Clinical Manifestations (With Mechanisms)

Because thyroid deficiency reduces metabolic energy across all tissues, symptoms typically develop insidiously over months or years and are often mistaken for normal aging or depression.

1. Metabolic and Thermoregulatory Features

  • Cold Intolerance and Hypothermia: How it comes about: Reduced Na+/K+-ATPase activity and slowed cellular oxidation markedly decrease internal heat generation (thermogenesis), causing patients to feel cold even in warm weather and risking severe hypothermia in myxedema coma.
  • Modest Weight Gain Despite Decreased Appetite: How it comes about: Lower basal metabolic rate reduces daily caloric burn, while retention of water and sodium by interstitial mucopolysaccharides adds fluid weight despite anorexia.

2. Neuropsychiatric and Neuromuscular Features

  • Fatigue, Lethargy, and Somnolence: How it comes about: Reduced mitochondrial ATP synthesis and slowed cerebral metabolism deprive skeletal muscle and brain neurons of energy, producing profound sluggishness and excessive daytime sleepiness.
  • Depression, Cognitive Slowing, and Memory Impairment: How it comes about: Thyroid hormone deficiency reduces central neurotransmitter turnover (serotonin, norepinephrine) and cerebral glucose utilization, causing poor concentration, apathy, psychomotor retardation, and dementia-like memory decline ("myxedema madness" in severe psychosis).
  • Hoarse, Deep, Slow Voice: How it comes about: Mucopolysaccharide infiltration and edema of the vocal cords thicken the cords, lowering vocal pitch and slowing speech articulation.
  • Delayed Relaxation Phase of Deep Tendon Reflexes (Woltman's Sign / "Hung-Up" Reflexes): How it comes about: Slowed sarcoplasmic reticulum calcium reuptake in skeletal muscle fibers delays muscle relaxation after tendon contraction (best seen at the Achilles tendon).
  • Muscle Cramps, Myalgia, and Proximal Weakness: How it comes about: Impaired muscle glycogenolysis and ATP turnover cause stiffness, aching, elevated creatine kinase (CK), and weakness.
  • Carpal Tunnel Syndrome (Hand Tingling and Numbness): How it comes about: Mucopolysaccharide swelling within the rigid carpal tunnel of the wrist compresses the median nerve.

3. Cardiovascular and Respiratory Features

  • Bradycardia and Reduced Cardiac Output: How it comes about: Downregulation of cardiac β1-receptors and reduced SA-node pacemaker firing slow the resting heart rate (< 60 bpm) and reduce stroke volume, contributing to exertional dyspnea and heart failure.
  • Diastolic Hypertension and Narrow Pulse Pressure: How it comes about: Peripheral vasoconstriction (compensating for low cardiac output and reduced endothelial nitric oxide) raises systemic vascular resistance and diastolic blood pressure.
  • Muffled Heart Sounds and Pericardial / Pleural Effusions: How it comes about: Increased capillary permeability to albumin and impaired lymphatic drainage allow protein-rich fluid to accumulate slowly in the pericardial and pleural cavities.
  • Hypoventilation and Obstructive Sleep Apnea: How it comes about: Blunted brainstem chemoreceptor drive to hypoxia/hypercapnia, respiratory muscle weakness, and macroglossia narrow the upper airway and depress ventilation.

4. Gastrointestinal Features

  • Constipation: How it comes about: Reduced smooth muscle peristalsis and autonomic tone slow colonic transit time, increasing water reabsorption and producing hard, infrequent stools (rarely progressing to paralytic ileus or megacolon).
  • Anorexia and Abdominal Bloating: How it comes about: Delayed gastric emptying and reduced digestive enzyme secretion cause early satiety and gaseous distension.

5. Dermatological, Mucocutaneous, and Facial Features

  • Dry, Coarse, Cool, Pale-Yellow Skin: How it comes about: Cutaneous vasoconstriction (to conserve heat) and reduced sweat/sebaceous gland output dry and cool the skin; impaired hepatic conversion of β-carotene to vitamin A causes yellowish carotenemia, while anemia adds pallor.
  • Coarse, Brittle Hair and Loss of Lateral Eyebrows (Queen Anne's Sign): How it comes about: Prolonged telogen (resting) phase of hair follicles impairs shaft growth, leading to diffuse hair thinning and loss of the outer third of the eyebrows.
  • Myxedema Facies (Puffy Eyelids, Coarse Features, Macroglossia): How it comes about: Subcutaneous glycosaminoglycan deposition causes non-pitting periorbital swelling, facial puffiness, and tongue enlargement (macroglossia).

6. Reproductive and Endocrine Features

  • Menorrhagia (Heavy, Prolonged Menstrual Bleeding) and Infertility: How it comes about: Altered estrogen metabolism, reduced SHBG, and frequent anovulatory cycles cause unopposed endometrial proliferation and heavy breakthrough bleeding (in contrast to the lighter periods of hyperthyroidism), alongside impaired ovulation and early miscarriage.
  • Galactorrhea (Inappropriate Milk Secretion): How it comes about: In primary hypothyroidism, high hypothalamic TRH stimulates pituitary lactotrophs as well as thyrotrophs, causing secondary hyperprolactinemia.
  • Loss of Libido and Erectile Dysfunction: How it comes about: Reduced free testosterone, hyperprolactinemia, and generalized fatigue impair sexual function.

7. Congenital Hypothyroidism (Cretinism) Features in Infants

  • Neonatal Presentation: Prolonged physiological jaundice, poor feeding, lethargy, hypotonia ("floppy baby"), hoarse cry, constipation, umbilical hernia, large tongue (macroglossia), puffy face, and widely open posterior/anterior fontanelles.
  • Late Untreated Features: Severe stunting (short stature with infantile limb proportions), delayed dentition and bone age, and permanent intellectual disability.

Advertisements

Diagnosis, Investigations, and Referral Criteria

Laboratory Pattern Interpretation

A bedside clinical assessment raises suspicion, but biochemical Thyroid Function Tests (TFTs) are required to confirm hypothyroidism and locate the defect along the HPT axis.

ConditionSerum TSHSerum Free T4Clinical Interpretation
Overt Primary HypothyroidismHigh (> 10 mIU/L typically)LowIntrinsic thyroid failure; requires lifelong levothyroxine replacement.
Subclinical HypothyroidismElevated (often 4.5–10 mIU/L)NormalMild thyroid failure; treat if TSH ≥ 10 mIU/L, pregnant, symptomatic, or positive anti-TPO antibodies; otherwise repeat in 3–6 months.
Secondary / Tertiary (Central) HypothyroidismLow or inappropriately normalLowPituitary or hypothalamic failure; assess other pituitary hormones (morning cortisol!) and perform pituitary MRI.
Non-Thyroidal Illness Syndrome ("Euthyroid Sick")Low, normal, or mildly elevatedLow or normal (low T3)Transient adaptation to severe acute non-thyroidal illness (sepsis, starvation); avoid starting levothyroxine unless true hypothyroidism is proven.

Additional Blood, Imaging, and Cardiac Investigations

  • Thyroid Autoantibodies: Elevated anti-TPO and anti-thyroglobulin antibodies confirm autoimmune Hashimoto's thyroiditis.
  • Supportive Blood Panel:
    • Complete Blood Count (CBC): Normocytic anemia (reduced erythropoietin) or macrocytic anemia (associated pernicious anemia / B12 deficiency).
    • Lipid Profile: Elevated total cholesterol, LDL, and triglycerides.
    • Serum Electrolytes, Glucose, and Creatine Kinase (CK): Check for hyponatremia, hypoglycemia (especially in myxedema coma), and elevated CK from myopathy.
    • Morning Serum Cortisol: Crucial before starting levothyroxine in suspected central hypothyroidism or myxedema coma to rule out concurrent adrenal insufficiency.
  • Imaging and Cardiac Tests:
    • Electrocardiogram (ECG): Sinus bradycardia, low-voltage QRS complexes, prolonged QT interval, and flattened/inverted T waves.
    • Chest X-ray / Echocardiogram: Enlarged globular cardiac silhouette ("water-bottle heart") indicating pericardial effusion, or pleural effusion.
    • Thyroid Ultrasound / FNA: Evaluates goitre size or suspicious nodules; Brain/Pituitary MRI is indicated if central hypothyroidism is found.

Red Flags and Referral Criteria (Uganda Clinical Guidelines 2023)

  • Emergency ICU/Hospital Referral: Suspected myxedema coma (hypothermia, altered consciousness, bradycardia, hypotension, or hypoventilation), symptomatic pericardial effusion, or severe heart failure.
  • Urgent Specialist Referral: Confirmed or suspected congenital hypothyroidism in neonates/infants (every week of delay impairs brain development), pregnancy (requires urgent dose escalation), central hypothyroidism, angina triggered by starting levothyroxine, or goitre with malignancy red flags.

Complications of Hypothyroidism

  • Myxedema Coma: Fatal if untreated (mortality 25–60%); commonly precipitated in elderly hypothyroid patients by cold weather, infections (pneumonia, UTI), sedatives/opioids/anesthetics, stroke, trauma, or stopping levothyroxine.
  • Cardiovascular Disease and Heart Failure: Chronic hyperlipidemia accelerates atherosclerosis and coronary artery disease; severe bradycardia, pericardial effusion, and diastolic hypertension worsen heart failure.
  • Obstetric and Neonatal Complications: Increased risk of miscarriage, gestational hypertension/pre-eclampsia, anemia, postpartum hemorrhage, low birth weight, and impaired fetal neurocognitive development.
  • Neuropsychiatric and Mechanical Complications: Severe depression, dementia-like cognitive decline, peripheral neuropathy/carpal tunnel syndrome, obstructive sleep apnea, and compressive symptoms if a large goitre is present.
  • Iatrogenic Over-Replacement Complications: Excess levothyroxine induces subclinical or overt thyrotoxicosis, precipitating angina pectoris, myocardial infarction, atrial fibrillation, and osteoporosis.

Medical, Pharmacological, and Emergency Management

Aims of Management

  • To restore circulating thyroid hormone levels to normal (euthyroid state) safely and sustainably.
  • To reverse hypometabolic symptoms, prevent myxedema coma, and preserve fetal brain development in pregnancy or infant neurodevelopment in congenital disease.
  • To avoid precipitating myocardial ischemia or arrhythmias during dose initiation in older or cardiac patients.

Lifelong Thyroid Hormone Replacement (Levothyroxine)

Levothyroxine sodium (synthetic T4) is the universal treatment of choice (Uganda Clinical Guidelines 2023, Section 8.1.7) because it provides stable physiological blood levels as peripheral tissues convert T4 to active T3 as needed.

  • Healthy Young and Middle-Aged Adults: Typical starting dose is 50–100 mcg orally once daily (or full replacement ~1.6 mcg/kg/day); usual maintenance dose is 100–200 mcg once daily.
  • Elderly Patients or Patients with Ischemic Heart Disease ("Start Low, Go Slow"): Start at a low dose—25–50 mcg once daily (or 12.5–25 mcg daily in frail cardiac patients)—and increase cautiously by 12.5–25 mcg every 4–6 weeks. Sudden full-dose replacement increases myocardial oxygen demand faster than coronary arteries can supply it, risking angina, myocardial infarction, or arrhythmias.
  • Pregnancy: Women with pre-existing hypothyroidism typically need a 25–30% increase in levothyroxine dose as soon as pregnancy is confirmed, with TFTs checked every 4–6 weeks during gestation.
  • Congenital Hypothyroidism (Infants/Children): Requires urgent weight-based initiation (higher mcg/kg doses than adults, e.g., 10–15 mcg/kg/day in neonates) under pediatric supervision to protect brain development.
  • Administration and Monitoring:
    • Take once daily on an empty stomach (30–60 minutes before breakfast, or consistently at bedtime 3–4 hours after the last meal) with plain water for reliable absorption.
    • Separate by at least 4 hours from iron supplements, calcium carbonate, antacids (aluminum/magnesium), sucralfate, and high-fiber/soy meals, which bind levothyroxine in the gut.
    • Re-check TSH every 4–8 weeks after any dose change until stable within target range (e.g., 0.5–4.5 mIU/L), then every 6–12 months. In central hypothyroidism, titrate using Free T4 (aiming for mid-to-upper normal range), not TSH.

Emergency Management of Myxedema Coma

  1. Admit to ICU / Resuscitation Bay and Secure ABCs: Assess airway patency (macroglossia and respiratory depression often necessitate endotracheal intubation and mechanical ventilation for hypercapnia/hypoxia) and administer humidified oxygen.
  2. Administer IV Hydrocortisone BEFORE or Alongside Thyroid Hormone: Give IV Hydrocortisone 100 mg every 8 hours initially. Crucial safety step: Giving levothyroxine alone accelerates cortisol clearance and can precipitate fatal acute adrenal crisis if coexisting adrenal insufficiency is present.
  3. IV Thyroid Hormone Replacement: Administer IV Levothyroxine (loading dose per specialist protocol, e.g., 200–400 mcg IV, followed by 50–100 mcg IV daily; add IV liothyronine where available in specialist units) or NG levothyroxine only if IV preparation is unavailable and gut perfusion is intact.
  4. Passive, Gradual Rewarming: Cover the patient with warm blankets in a warm room. Avoid rapid active external rewarming (heating pads/hot water bottles), which causes sudden peripheral vasodilation and vascular collapse (shock).
  5. Careful Fluid, Glucose, and Electrolyte Support: Treat hypoglycemia with IV dextrose; correct hypotension cautiously with isotonic fluids (avoid excess free water that worsens hyponatremia).
  6. Treat Precipitating Cause and Avoid CNS Depressants: Draw blood/urine cultures and start empiric broad-spectrum antibiotics if infection is suspected; strictly avoid opioids, benzodiazepines, and sedatives because slowed hepatic clearance causes prolonged respiratory depression.

Pharmacokinetics and Pharmacodynamics of Hypothyroidism Medications

MedicationPharmacodynamics (Mechanism & Effect)Pharmacokinetics (ADME)Key Nursing & Safety Implications
Levothyroxine (Synthetic T4)Identical to endogenous thyroxine; peripherally deiodinated to active T3, which binds nuclear thyroid receptors to upregulate gene transcription, basal metabolic rate, cardiac contractility, thermogenesis, and growth.
  • Absorption: 60–80% absorbed in small intestine (fasting); impaired by food, coffee, calcium, iron, antacids, and PPIs.
  • Distribution: > 99% bound to TBG, transthyretin, and albumin.
  • Metabolism & Half-Life: Peripheral deiodination to T3; hepatic conjugation; very long half-life (~6–7 days, longer in hypothyroidism—steady state takes 4–6 weeks).
  • Excretion: Bile/feces and urine.
Take on an empty stomach 30–60 min before breakfast; separate 4 hours from iron/calcium/antacids. Do not expect immediate symptom relief (full effect takes 4–6 weeks). Watch for palpitations, chest pain, tremor, or sweating (over-replacement); rifampicin, carbamazepine, and phenytoin accelerate clearance (may need higher dose).
Liothyronine (Synthetic T3 — Specialist / Myxedema Coma)Direct active thyroid hormone binding nuclear receptors without requiring peripheral T4→T3 conversion; rapid metabolic and cardiovascular onset.Near-complete oral absorption (~95%); lower protein binding than T4; short half-life (~1–2 days); hepatic conjugation and fecal/renal excretion.Reserved for specialist myxedema coma protocols or short-term diagnostic use; rapid peak increases risk of acute arrhythmias and angina compared with levothyroxine.
Hydrocortisone (IV in Myxedema Coma)Glucocorticoid replacing cortisol deficiency, supporting vascular catecholamine responsiveness, maintaining blood glucose, and preventing adrenal crisis when metabolic rate rises.Immediate bioavailability via IV route; hepatic metabolism; renal excretion; plasma half-life ~1.5 h (biological 8–12 h).Always administer before or concurrently with IV levothyroxine in myxedema coma until adrenal insufficiency is ruled out.
Dietary Iodine / Iodized Salt (Prophylaxis)Supplies essential iodide substrate for thyroid peroxidase to synthesize T3 and T4, preventing compensatory TSH hyperplasia (endemic goitre).Rapid GI absorption as iodide; concentrated in thyroid follicular cells via sodium-iodide symporter; excess excreted unchanged in urine.Promote universal use of iodized table salt in households; avoid mega-dose iodine supplements, which can paradoxically suppress or overstimulate thyroid function.

Advertisements

Nursing Management of Hypothyroidism

Nursing Care Plan for a Patient with Hypothyroidism (NANDA-I 2024–2026)

This care plan applies current NANDA-I 2024–2026 nursing diagnoses (Hypothermia, Decreased cardiac output, Constipation, Risk for ineffective breathing pattern, and Inadequate health knowledge) prior to detailed nursing interventions.

AssessmentDiagnosis (NANDA-I 2024–2026)Planning (Goals & Expected Outcomes)Implementation / InterventionsRationaleEvaluation
  • Subjective: Patient complains of feeling severely cold even under heavy clothing.
  • Objective: Core temperature 35.1°C, cool dry pale skin, shivering absent (blunted thermoregulation).
Hypothermia related to decreased basal metabolic rate and impaired cellular thermogenesis secondary to thyroid hormone deficiency as evidenced by body temperature 35.1°C and cool skin.

Restore and maintain normal core body temperature within 12–24 hours safely.

Expected outcomes:

  • Core temperature 36.5–37.2°C.
  • Patient reports thermal comfort without hemodynamic collapse.
  1. Monitor core temperature, heart rate, and blood pressure every 1–2 hours.
  2. Provide passive rewarming using pre-warmed cotton blankets, socks, and a warm draft-free room; avoid electric heating pads or hot water bottles.
  3. Administer prescribed levothyroxine (and IV hydrocortisone if myxedema coma) promptly.
  4. Protect dry fragile skin with gentle emollients and reposition every 2 hours.
  1. Tracks rewarming speed and detects falling blood pressure early.
  2. Passive warming raises core temperature gradually without causing sudden peripheral vasodilation, shock, or thermal burns on numb skin.
  3. Gradually restores cellular metabolic heat production.
  4. Prevents pressure injuries and cracking of severely dry, edematous skin.
Within 16 hours of passive warming and hormone replacement, temperature rose steadily to 36.6°C with stable BP.
  • Subjective: Patient reports severe fatigue, dizziness on standing, and exertional breathlessness.
  • Objective: HR 48 bpm, BP 94/66 mmHg, muffled heart sounds, generalized non-pitting edema.
Decreased cardiac output related to reduced myocardial contractility, bradycardia, and pericardial effusion secondary to hypothyroidism as evidenced by HR 48 bpm, hypotension, and exertional dyspnea.

Maintain adequate organ perfusion and prevent cardiac ischemia during hormone initiation.

Expected outcomes:

  • Heart rate ≥ 60 bpm and BP stable at patient's normal baseline.
  • Patient remains free from chest pain, syncope, and worsening dyspnea.
  1. Monitor vital signs, ECG rhythm, capillary refill, and urine output closely.
  2. Initiate low-dose levothyroxine as ordered ("start low, go slow" in older/cardiac patients) and assess for angina or palpitations after dose changes.
  3. Space nursing activities with frequent rest periods and elevate head of bed if dyspneic.
  4. Avoid rapid excessive IV fluid boluses unless hypotensive and ordered.
  1. Identifies worsening bradycardia, heart block, or cardiac tamponade early.
  2. Gradual titration restores stroke volume safely without overwhelming coronary blood flow.
  3. Conserves limited cellular energy and prevents exertional myocardial ischemia.
  4. Hypothyroid hearts and impaired free-water clearance tolerate fluid overload poorly.
Patient maintained stable BP (110/74 mmHg), HR improved to 64 bpm over recovery, and no chest pain occurred.
  • Subjective: Patient reports no bowel movement for 5 days, abdominal fullness, and poor appetite.
  • Objective: Hypoactive bowel sounds, mild abdominal distension, hard stool on examination.
Constipation related to decreased gastrointestinal motility and slowed smooth muscle peristalsis as evidenced by absence of stool for 5 days and hypoactive bowel sounds.

Re-establish regular, soft bowel movements within 3–5 days without impaction.

Expected outcomes:

  • Patient will pass soft, formed stool at least every 2–3 days.
  • Active bowel sounds present with reduced abdominal distension.
  1. Auscultate bowel sounds, assess abdominal girth/tenderness, and record stool frequency daily.
  2. Increase dietary fiber gradually (fruits, vegetables, whole grains) and encourage warm oral fluids unless fluid-restricted for hyponatremia.
  3. Encourage gentle progressive ambulation as tolerated and administer prescribed stool softeners (avoid routine enemas/stimulants if ileus suspected).
  1. Distinguishes simple hypomotility from paralytic ileus or myxedema megacolon.
  2. Adds stool bulk and softens fecal mass once peristalsis resumes.
  3. Physical movement stimulates colonic motility while stool softeners prevent straining (which triggers vagal bradycardia).
Within 4 days, patient had active bowel sounds and passed soft formed stools every 2 days without straining.
  • Subjective: Family reports loud snoring, pauses in breathing during sleep, and increasing drowsiness.
  • Objective: RR 11 breaths/min, SpO2 91%, macroglossia, lethargy, risk of hypercapnia.
Risk for ineffective breathing pattern (and actual impaired gas exchange in severe myxedema) related to blunted central ventilatory drive, respiratory muscle weakness, macroglossia, and pleural effusion.

Maintain patent airway and adequate arterial oxygenation throughout admission.

Expected outcomes:

  • Respiratory rate 12–20 breaths/min and SpO2 ≥ 94%.
  • Patient remains alert and easily rousable without respiratory depression.
  1. Monitor RR, depth, SpO2, level of consciousness, and ABGs (PaCO2) regularly.
  2. Nurse in semi-Fowler's or lateral position to keep enlarged tongue from obstructing the airway; encourage deep breathing/coughing hourly.
  3. Strictly avoid sedatives, opioids, and hypnotics; keep suction and airway/intubation equipment accessible in severe myxedema.
  1. Detects progressive hypoventilation and CO2 narcosis before respiratory arrest occurs.
  2. Maximizes diaphragmatic descent and maintains upper airway patency.
  3. Slowed drug metabolism causes profound, prolonged respiratory arrest even after standard sedative doses.
Patient maintained RR 16 breaths/min, SpO2 96%, and improved alertness without sedative exposure.
  • Subjective: Patient asks if levothyroxine can be stopped once fatigue improves and takes it together with morning tea and iron tablets.
  • Objective: Newly diagnosed hypothyroidism; unaware of lifelong therapy, interactions, and toxicity signs.
Inadequate health knowledge related to unfamiliarity with lifelong thyroid hormone replacement, levothyroxine administration timing, and under-/over-replacement symptoms as evidenced by taking tablets with iron and tea.

Demonstrate accurate lifelong self-management prior to discharge.

Expected outcomes:

  • Patient will explain empty-stomach timing and 4-hour separation from iron/calcium/antacids.
  • Patient will list symptoms of both under- and over-replacement and need for lifelong adherence.
  1. Explain that hypothyroidism usually requires lifelong daily levothyroxine and must never be stopped just because symptoms improve.
  2. Teach proper administration: 30–60 minutes before breakfast with plain water, separated by 4 hours from iron, calcium, and antacids.
  3. Review signs of under-replacement (fatigue, coldness, constipation) and over-replacement (palpitations, chest pain, tremor, sweating, insomnia) and need for regular TSH checks (and immediate dose review if pregnant).
  4. Confirm understanding using the teach-back method.
  1. Prevents relapse into severe hypothyroidism and myxedema coma.
  2. Prevents chelation/malabsorption in the gut and keeps serum hormone levels stable.
  3. Enables early clinician dose adjustment and protects cardiac health and fetal neurodevelopment.
  4. Verifies practical patient readiness for safe long-term home care.
At discharge, patient accurately demonstrated correct morning levothyroxine routine, 4-hour mineral separation, and warning signs via teach-back.

Detailed Nursing Assessments and Interventions

  1. Assess Metabolic and Neurological Status: Monitor core temperature, level of consciousness, orientation, speech clarity, and deep tendon reflexes; watch closely for worsening lethargy or confusion signaling impending myxedema coma.
  2. Ensure Safe Rewarming and Skin Integrity: Use passive rewarming (warm room, blankets) rather than external heating devices; apply gentle moisturizers to dry scaly skin, avoid harsh soaps, and protect pressure areas over myxedematous tissues.
  3. Monitor Cardiovascular and Respiratory Function: Assess apical pulse, BP, ECG, heart/lung sounds, peripheral edema, RR, and SpO2; report chest pain or arrhythmias immediately after initiating levothyroxine.
  4. Administer Medications Safely and Avoid CNS Depressants: Give levothyroxine consistently on an empty stomach; check all concurrent drugs for absorption interference (iron, calcium, antacids) or sedative effects (question/hold routine opioids, benzodiazepines, or sleep aids in severe hypothyroidism).
  5. Manage Nutrition, Fluid Balance, and Elimination: Provide a well-balanced, nutrient-dense, lower-calorie high-fiber diet if obese/constipated; monitor fluid intake/output and serum sodium; track bowel movements to prevent fecal impaction.
  6. Support Emotional Well-Being: Reassure the patient and family that sluggishness, forgetfulness, and depressed mood are biological effects of hormone deficiency that improve steadily over weeks of treatment; communicate slowly, clearly, and patiently.

Advice on Discharge

  • Lifelong Daily Adherence: Take levothyroxine at the exact same time every morning on an empty stomach (30–60 minutes before breakfast) with water; never skip doses or stop taking the medicine without medical advice.
  • Medication and Supplement Separation: Inform every doctor and pharmacist about levothyroxine use, and separate iron tablets, calcium supplements, and antacids by at least 4 hours.
  • Recognizing Under- or Over-Replacement: Report persistent tiredness, weight gain, constipation, or feeling cold (dose may be too low), as well as chest pain, racing heartbeat, trembling hands, sweating, or anxiety (dose may be too high).
  • Pregnancy and Follow-Up: Women of childbearing age must notify their clinician immediately upon becoming pregnant so the levothyroxine dose can be increased promptly; attend scheduled clinic reviews for TSH/Free T4 blood tests.

Prevention, Patient Education, and Uganda Clinical Context

  • Primary Prevention: Universal use of iodized table salt and proper preparation of goitrogenic foods (such as thoroughly soaking/fermenting and cooking cassava) prevent endemic iodine-deficiency goitre, adult hypothyroidism, and congenital cretinism.
  • Secondary Prevention (Early Screening): Routine periodic TSH monitoring for patients treated with thyroidectomy or radioactive iodine, pregnant women with thyroid risk factors, patients on lithium or amiodarone, and neonates displaying prolonged jaundice or hypotonia.
  • Uganda-Specific Clinical Considerations: While universal salt iodization has dramatically reduced severe endemic goitre in Uganda, both iodine-related disorders and autoimmune Hashimoto's thyroiditis remain clinically important. Because TSH and Free T4 assays may be unavailable at lower-level health centres (HC II–HC III), nurses and clinicians must maintain high clinical suspicion for slow-onset fatigue, cold intolerance, constipation, bradycardia, and periorbital puffiness, ensure timely referral to hospitals or Regional Referral Hospitals for confirmatory testing and safe cardiac titration, and reinforce consistent daily access to levothyroxine.

References

  • Ministry of Health, Republic of Uganda. Uganda Clinical Guidelines (UCG) 2023. Chapter 8: Endocrine Disorders — Section 8.1.7 (Hypothyroidism).
  • Herdman TH, Kamitsuru S, Lopes CT (eds). NANDA International Nursing Diagnoses: Definitions and Classification, 2024–2026 (13th ed.). Thieme; 2024.

Leave a Comment

Your email address will not be published. Required fields are marked *

Want notes in PDF? Join our classes!!

Send us a message on WhatsApp
0726113908

Scroll to Top
Enable Notifications OK No thanks